{"id":"NCT01855789","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX","officialTitle":"A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11-07","primaryCompletion":"2016-10-14","completion":"2016-10-14","firstPosted":"2013-05-17","resultsPosted":"2017-12-26","lastUpdate":"2017-12-26"},"enrollment":718,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Tocilizumab (TCZ)","otherNames":["Actemra"]},{"type":"DRUG","name":"Methotrexate (MTX)","otherNames":[]},{"type":"DRUG","name":"Placebo (PBO)","otherNames":[]}],"arms":[{"label":"Non-Randomized Participants (TCZ + MTX)","type":"EXPERIMENTAL"},{"label":"Randomized Participants (TCZ + MTX)","type":"EXPERIMENTAL"},{"label":"Randomized Participants (TCZ + PBO)","type":"ACTIVE_COMPARATOR"}],"summary":"This randomized, multicenter, double-blind, parallel group study will evaluate the impact of MTX discontinuation on the efficacy of SC TCZ in participants with moderate to severe active rheumatoid arthritis who have an inadequate response to current MTX therapy. Participants will initiate treatment with TCZ weekly or every 2 weeks along with MTX at a stable dose orally in an open-label manner for 24 weeks. Participants with a disease activity score based on 28 joints (DAS28) less than or equal to (\\</=) 3.2 at Week 24, will be randomized to either continue receiving a stable dose of MTX or to switch to matching placebo up to Week 52. Participants without a DAS28 score \\</=3.2 at Week 24, will continue the same treatment in a non-randomized open-label manner up to Week 52.","primaryOutcome":{"measure":"Change From Week 24 in Disease Activity Score Based on 28 Joints (DAS28) Score at Week 40","timeFrame":"Week 24, Week 40","effectByArm":[{"arm":"Period 2: Randomized Participants (TCZ + MTX)","deltaMin":2.13,"sd":0.816},{"arm":"Period 2: Randomized Participants (TCZ + PBO)","deltaMin":2.11,"sd":0.822}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":19},"locations":{"siteCount":155,"countries":["United States"]},"refs":{"pmids":["29575803"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":72,"n":713},"commonTop":["Alanine aminotransferase increased","Upper respiratory tract infection","Hepatic enzyme increased","Aspartate aminotransferase increased","Urinary tract infection"]}}